Study of BG-85738 for advanced solid tumors with RAS mutations
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new drug called BG-85738, which may target cancer cells that have a specific change (mutation) in the RAS gene. The goal is to see if it is safe and works against advanced or spreading solid tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of solid tumor that is advanced, has spread, and cannot be removed with surgery.
- Your tumor has a specific change in a gene called RAS (known as a RAS mutation), confirmed by a test.
- You have not had prior treatment with a RAS-targeted therapy, except for certain cases with G12C inhibitors for lung or colorectal cancer.
- You do not have untreated or uncontrolled brain metastases, active hepatitis C, or untreated HIV.
- You have not had another cancer within the past 3 years, except for certain curable skin cancers or early-stage cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial tests a new oral drug, GFH276, in people with advanced lung cancer that has a change in a gene called RAS. The drug is designed to target cancers with this specific mutation, and the study aims to find out if it is safe and effective for patients who have not had prior treatment for their advanced disease.
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
This study tests a new drug called BG-C0979 for advanced solid tumors that have not responded to standard treatments. It may be given alone or with other therapies to see if it can shrink tumors or slow cancer growth.
Hear when a new RAS Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.